Details of the Drug Combination

General Information of Drug Combination (ID: DCMD4D4)

Drug Combination Name
Tadalafil Dapoxetine
Indication
Disease Entry Status REF
Premature Ejaculation Phase 3 [1]
Component Drugs Tadalafil   DMJZHT1 Dapoxetine   DMV6KFY
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Tadalafil
Disease Entry ICD 11 Status REF
Benign prostatic hyperplasia GA90 Approved [2]
Erectile dysfunction HA01.1 Approved [3]
Plasma cell myeloma 2A83.1 Approved [2]
Pulmonary hypertension BB01 Approved [2]
Priapism N.A. Investigative [2]
Tadalafil Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Phosphodiesterase 5A (PDE5A) TTJ0IQB PDE5A_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Tadalafil Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [6]
------------------------------------------------------------------------------------
Tadalafil Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Tadalafil Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
cGMP-specific 3',5'-cyclic phosphodiesterase (PDE5A) OTT8Q1AP PDE5A_HUMAN Decreases Activity [8]
------------------------------------------------------------------------------------
Indication(s) of Dapoxetine
Disease Entry ICD 11 Status REF
Premature ejaculation HA03.0Z Phase 4 [4]
Dapoxetine Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [9]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [10]
Dimethylaniline oxidase 1 (FMO1) DEJ73Q9 FMO1_HUMAN Metabolism [9]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04361305) Observational Study of Pharmacological Treatment for Premature Ejaculation Concurrent With Erectile Dysfunction
2 Tadalafil FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7299).
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7901).
5 Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31.
6 In Vitro P-Glycoprotein-Mediated Transport of Tadalafil: A Comparison with Sildenafil. Biol Pharm Bull. 2017;40(8):1314-1319.
7 Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation. Biol Pharm Bull. 2015;38(1):58-65.
8 Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. Expert Opin Drug Saf. 2005 May;4(3):531-40. doi: 10.1517/14740338.4.3.531.
9 Pharmacokinetics of single and multiple escalating doses of dapoxetine in healthy volunteers. Clinical Pharmacology Therapeutics, 2004, 75(2):P32.
10 Dapoxetine: a new option in the medical management of premature ejaculation. Ther Adv Urol. 2012 Oct;4(5):233-51.